VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE)-- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies ...
Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumoursVANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- . (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) ...
Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...
kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results